| Bioactivity | Onvitrelin ucalontide ([Phor18-LHRH (338613)]) is an analogue of luteinizing hormone releasing hormone (LHRH) with antineoplastic activity. Onvitrelin ucalontide is a peptide with sequences of KFAKFAKKFAKFAKKFAKQHWSYGLRPG. Onvitrelin ucalontide effectively inhibits breast cancer, ovarian cancer and prostate cancer xenografts in mouse model[1][2]. |
| Name | Onvitrelin ucalontide |
| CAS | 1174415-90-7 |
| Sequence | Lys-Phe-Ala-Lys-Phe-Ala-Lys-Lys-Phe-Ala-Lys-Phe-Ala-Lys-Lys-Phe-Ala-Lys-Gln-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly |
| Shortening | KFAKFAKKFAKFAKKFAKQHWSYGLRPG |
| Formula | C163H243N43O32 |
| Molar Mass | 3316.94 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Onvitrelin ucalontide
CAS: 1174415-90-7 F: C163H243N43O32 W: 3316.94
Onvitrelin ucalontide () is an analogue of luteinizing hormone releasing hormone (LHRH) with antineoplastic activity. On
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.